Navigation Links
The mouse that ROR'ed
Date:1/2/2014

Researchers at the University of California, San Diego School of Medicine report that an oncogene dubbed ROR1, found on chronic lymphocytic leukemia (CLL) B cells but not normal adult tissues, acts as an accelerant when combined with another oncogene, resulting in a faster-developing, more aggressive form of CLL in mice.

The findings, published in the Dec. 30, 2013 Online Early Edition of PNAS, suggest ROR1 could be an important therapeutic target for patients with CLL, the most common form of blood cancer. Prevalence of CLL in the United States is high: 1 in 20 people over the age of 40 could have apparently pre-cancerous CLL-like cells in their blood. These people may develop actual CLL at a rate of about 1 percent per year. More than 15,000 new cases of CLL are diagnosed each year in the United States. Roughly 4,400 patients with CLL die annually.

The work by principal investigator Thomas Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, and colleagues continues a series of discoveries about ROR1. Previously, for example, they found an association between ROR1 and the epithelial-mesenchymal transition the process that occurs during embryogenesis when cells migrate and then grow into new organs during early development. CLL cells exploit ROR1 to spread disease. Called metastasis, it is responsible for 90 percent of cancer-related deaths.

In the PNAS paper, Kipps and colleagues created transgenic mice that expressed human ROR1, then observed that these mice produced B cells (a kind of white blood cell) that were abnormal and resembled human CLL cells while non-transgenic littermates did not.

Next they crossed the ROR1 mice with another transgenic mouse-type that produces an oncogene called TCL1. Oncogenes are genes that can lead to cancer development if over-expressed or mutated. The progeny of these cross-bred mice possessed both oncogenes ROR1 and TCL1 and consequently displayed an even greater proclivity toward developing aggressive, fast-acting CLL.

When researchers treated the mice with an anti-ROR1 monoclonal antibody that reduces levels of ROR1, the CLL cells were impaired and more vulnerable to treatment and destruction. Based on these findings, Kipps said investigators at UC San Diego Moores Cancer Center are planning clinical trials in 2014 using a humanized monoclonal antibody that has the same type of activity against human leukemia or cancer cells that express ROR1.


'/>"/>

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related biology news :

1. H. pylori vaccine shows promise in mouse studies
2. New book on mouse models of cancer from Cold Spring Harbor Laboratory Press
3. Mouse studies reveal promising vitamin D-based treatment for MS
4. Elevated levels of copper in amyloid plaques associated with neurodegeneration in mouse models of AD
5. New agent inhibits HCV replication in mouse models -- No resistance seen
6. Cat and mouse: A single gene matters
7. New mouse viruses could aid hepatitis research
8. Omega-3s from fish vs. fish oil pills better at maintaining blood pressure in mouse model
9. UT Southwestern scientists make mouse model of human cancer, demonstrate cure
10. Researchers generate a mutant mouse model useful in the treatment of neuromuscular diseases
11. Transplanted neural stem cells slows als onset and progression in mouse models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela ... The Chancellor came to the DERMALOG stand together with the Japanese Prime ... partner country. At the largest German biometrics company the two government leaders ... iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... ... 27, 2017 , ... Oncolinx, a spin-out of the Center ... truly taken their cancer research out of this world. On April 22, 2017, ... to the International Space Station’s (ISS) U.S. National Laboratory, managed by the Center ...
(Date:4/27/2017)... Luxembourg (PRWEB) , ... April 27, 2017 , ... Mitotech ... study in Leber’s Hereditary Optic Neuropathy (LHON) patients. LHON is a rare devastating genetic ... efficacy of SkQ1 eye drops in a group of 20 patients carrying 11778, 14484 ...
(Date:4/27/2017)... ... 2017 , ... Arrowhead Publishers is pleased to announce the ... San Diego, CA on September 27-28, 2017. Leaders from the pharmaceutical, biotech, device ... the treatment of various types of pain. There are also extended networking opportunities, ...
(Date:4/27/2017)... ... April 27, 2017 , ... Sierra Instruments announces ... capillary thermal mass flow technology provide exponentially more accurate mass flow data than ... of all industrial processes—such as those involving chemical reactions, combustion, respiration, pharmaceutical, and ...
Breaking Biology Technology: